Guobang Pharma Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	6,068	5,988	5,867	5,327	5,704	4,493
Other Revenue	23.8	23.8	23.85	22.35	17.33	12.43
Revenue	6,092	6,011	5,891	5,349	5,721	4,505
Revenue Growth (YoY)	1.67%	2.05%	10.12%	-6.49%	26.98%	7.11%
Cost of Revenue	4,594	4,483	4,455	4,141	4,190	3,212
Gross Profit	1,499	1,528	1,435	1,209	1,531	1,294
Selling, General & Admin	361.69	366.34	345.57	365.25	339.93	297.29
Research & Development	200.82	209.83	215.05	190.51	197.54	155.27
Other Operating Expenses	39.03	32.27	26.73	30.96	31.9	23.67
Operating Expenses	607.19	614.1	599.43	579.55	581.08	478.27
Operating Income	891.33	914.38	835.91	629.3	949.97	815.55
Interest Expense	-23.92	-23.92	-27.28	-22.58	-16.55	-28.72
Interest & Investment Income	34.46	34.56	42.89	65	48.9	22.66
Currency Exchange Gain (Loss)	-9.17	-9.17	32.46	22.04	58.72	-14.48
Other Non Operating Income (Expenses)	-35.72	-4.42	-5.48	-7.41	-4.31	-2.13
EBT Excluding Unusual Items	856.98	911.43	878.5	686.35	1,037	792.88
Gain (Loss) on Sale of Investments	13.12	12.92	14.4	10.34	4.56	6.26
Gain (Loss) on Sale of Assets	24.81	24.81	-9.11	0.72	-15.84	0.3
Asset Writedown	-15.06	-7.67	-6.54	-5.8	-0.05	-9.31
Other Unusual Items	9.76	9.76	10.71	6.04	10.24	16.65
Pretax Income	889.6	951.26	887.97	697.65	1,036	806.78
Income Tax Expense	126.16	133.69	107.39	87.67	115.02	100.55
Earnings From Continuing Operations	763.44	817.57	780.58	609.98	920.62	706.23
Minority Interest in Earnings	3.03	3.25	1.02	2.49	0.28	-0.2
Net Income	766.47	820.82	781.6	612.46	920.9	706.03
Net Income to Common	766.47	820.82	781.6	612.46	920.9	706.03
Net Income Growth	-3.93%	5.02%	27.62%	-33.49%	30.43%	-12.84%
Shares Outstanding (Basic)	552	555	558	557	558	512
Shares Outstanding (Diluted)	552	555	558	557	558	512
Shares Change (YoY)	-1.79%	-0.66%	0.27%	-0.24%	9.09%	8.01%
EPS (Basic)	1.39	1.48	1.40	1.10	1.65	1.38
EPS (Diluted)	1.39	1.48	1.40	1.10	1.65	1.38
EPS Growth	-2.18%	5.71%	27.27%	-33.33%	19.56%	-19.30%
Free Cash Flow	776.02	281.57	287.29	-231.68	213.92	-624.23
Free Cash Flow Per Share	1.41	0.51	0.52	-0.42	0.38	-1.22
Dividend Per Share	0.600	0.600	0.606	0.302	0.600	0.700
Dividend Growth	-0.96%	-0.96%	100.92%	-49.74%	-14.29%	-
Gross Margin	24.60%	25.43%	24.37%	22.60%	26.76%	28.72%
Operating Margin	14.63%	15.21%	14.19%	11.76%	16.61%	18.10%
Profit Margin	12.58%	13.65%	13.27%	11.45%	16.10%	15.67%
Free Cash Flow Margin	12.74%	4.68%	4.88%	-4.33%	3.74%	-13.86%
EBITDA	1,379	1,391	1,269	950.43	1,210	1,016
EBITDA Margin	22.64%	23.14%	21.55%	17.77%	21.15%	22.56%
D&A For EBITDA	487.86	476.96	433.38	321.14	260.21	200.9
EBIT	891.33	914.38	835.91	629.3	949.97	815.55
EBIT Margin	14.63%	15.21%	14.19%	11.76%	16.61%	18.10%
Effective Tax Rate	14.18%	14.05%	12.09%	12.57%	11.11%	12.46%
Revenue as Reported	6,011	6,011	5,891	5,349	5,721	4,505
Advertising Expenses	-	2.66	1.94	1.52	3.42	1.2

Source: S&P Global Market Intelligence. Standard template. Financial Sources.